Sandoz Group (OTCMKTS:SDZNY) Shares Gap Up – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) gapped up before the market opened on Wednesday . The stock had previously closed at $85.80, but opened at $89.85. Sandoz Group shares last traded at $89.30, with a volume of 1,912 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Sandoz Group to a “strong-buy” rating in a research note on Wednesday, April 1st. Barclays upgraded shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada lowered shares of Sandoz Group from a “moderate buy” rating to a “hold” rating in a research report on Monday, March 23rd. Three equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Strong Buy”.

Sandoz Group Stock Up 1.8%

The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77. The business has a fifty day simple moving average of $83.47 and a 200-day simple moving average of $80.59.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.